Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

被引：0
|
作者：
Venturella, Fabio [1 ]
Cancellieri, Giulia [1 ]
Giammanco, Marco [2 ]
Almerico, Anna Maria [1 ]
Aleo, Igor Daniele
Liga, Anastasia Valentina [1 ]
Mortillaro, Francesca [1 ]
Mistretta, Irene [1 ]
机构：
[1] Univ Palermo, Biol Chem & Pharmaceut Sci & Technol Dept, Palermo, Italy
[2] Univ Palermo, Surg Oncol & Stomatol Disciplines Dept, Palermo, Italy
来源：
JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE | 2023年 / 96卷 / 01期
关键词：
cancer; lung; immuno-oncology; Nivolumab; SAFETY;
D O I：
10.4081/jbr.2023.11027
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer ( NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality
    Merimsky, O.
    Shamai, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2425 - S2425
  • [32] Is chemotherapy rechallenge feasible in advanced-stage non-small-cell lung cancer?
    Mignard, Xavier
    Ruppert, Anne-Marie
    Lavole, Armelle
    Vieira, Thibault
    Rozensztajn, Nathalie
    Cadranel, Jacques
    Wislez, Marie
    BULLETIN DU CANCER, 2019, 106 (09) : 725 - 733
  • [33] Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment
    Samejima, Yumiko
    Iuchi, Atsuhiko
    Kanai, Tomohiro
    Noda, Yoshimi
    Nasu, Shingo
    Tanaka, Ayako
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Harada, Hiroshi
    Ezumi, Akira
    Ueda, Kayo
    Kawahara, Kunimitsu
    Hirashima, Tomonori
    INTERNAL MEDICINE, 2020, 59 (16) : 2003 - 2008
  • [34] Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Tsiara, Anna
    Liontos, Michalis
    Kaparelou, Maria
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [35] Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
    Putzu, Carlo
    Cortinovis, Diego Luigi
    Colonese, Francesca
    Canova, Stefania
    Carru, Ciriaco
    Zinellu, Angelo
    Paliogiannis, Panagiotis
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (09) : 1349 - 1353
  • [36] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors
    Bylicki, Olivier
    Barazzutti, Helene
    Paleiron, Nicolas
    Margery, Jacques
    Assie, Jean-Baptiste
    Chouaid, Christos
    BIODRUGS, 2019, 33 (02) : 159 - 171
  • [37] New targeted treatments for non-small-cell lung cancer - role of nivolumab
    Zago, Giulia
    Muller, Mirte
    van den Heuvel, Michel
    Baas, Paul
    BIOLOGICS-TARGETS & THERAPY, 2016, 10 : 103 - 117
  • [38] Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer
    Enomoto, T.
    Tamiya, A.
    Matsumoto, K.
    Adachi, Y.
    Azuma, K.
    Inagaki, Y.
    Kouno, S.
    Taniguchi, Y.
    Saijo, N.
    Okishio, K.
    Atagi, S.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (03) : 582 - 590
  • [39] Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
    Carlo Putzu
    Diego Luigi Cortinovis
    Francesca Colonese
    Stefania Canova
    Ciriaco Carru
    Angelo Zinellu
    Panagiotis Paliogiannis
    Cancer Immunology, Immunotherapy, 2018, 67 : 1349 - 1353
  • [40] Immunotherapy in advanced non-small-cell lung cancer withEGFRmutations
    Liu, Fangfang
    Yuan, Xun
    Jiang, Jizong
    Chu, Qian
    IMMUNOTHERAPY, 2020, 12 (16) : 1195 - 1207
12345